HRP20241046T1 - Antagonisti crf1 receptora za liječenje kongenitalne adrenalne hiperplazije - Google Patents

Antagonisti crf1 receptora za liječenje kongenitalne adrenalne hiperplazije Download PDF

Info

Publication number
HRP20241046T1
HRP20241046T1 HRP20241046TT HRP20241046T HRP20241046T1 HR P20241046 T1 HRP20241046 T1 HR P20241046T1 HR P20241046T T HRP20241046T T HR P20241046TT HR P20241046 T HRP20241046 T HR P20241046T HR P20241046 T1 HRP20241046 T1 HR P20241046T1
Authority
HR
Croatia
Prior art keywords
receptor antagonist
crf1 receptor
glucocorticoid
use according
crf1
Prior art date
Application number
HRP20241046TT
Other languages
English (en)
Croatian (hr)
Inventor
Dimitri E. Grigoriadis
Original Assignee
Neurocrine Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52450623&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20241046(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurocrine Biosciences, Inc. filed Critical Neurocrine Biosciences, Inc.
Publication of HRP20241046T1 publication Critical patent/HRP20241046T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HRP20241046TT 2014-01-21 2015-01-21 Antagonisti crf1 receptora za liječenje kongenitalne adrenalne hiperplazije HRP20241046T1 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461929941P 2014-01-21 2014-01-21
US201461981033P 2014-04-17 2014-04-17
US201462069155P 2014-10-27 2014-10-27
EP15702917.4A EP3096756B1 (en) 2014-01-21 2015-01-21 Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
PCT/US2015/012315 WO2015112642A1 (en) 2014-01-21 2015-01-21 Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia

Publications (1)

Publication Number Publication Date
HRP20241046T1 true HRP20241046T1 (hr) 2024-11-08

Family

ID=52450623

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20241046TT HRP20241046T1 (hr) 2014-01-21 2015-01-21 Antagonisti crf1 receptora za liječenje kongenitalne adrenalne hiperplazije

Country Status (24)

Country Link
US (5) US20170020877A1 (https=)
EP (2) EP4450070A1 (https=)
JP (5) JP6585625B2 (https=)
KR (2) KR102258522B1 (https=)
CN (2) CN106102740A (https=)
AU (4) AU2015209452C1 (https=)
BR (1) BR112016016975B1 (https=)
CA (2) CA2936974A1 (https=)
DK (1) DK3096756T3 (https=)
ES (1) ES2984706T3 (https=)
FI (1) FI3096756T3 (https=)
HR (1) HRP20241046T1 (https=)
HU (1) HUE068315T2 (https=)
IL (5) IL296683B2 (https=)
LT (1) LT3096756T (https=)
MX (3) MX389004B (https=)
NZ (1) NZ722122A (https=)
PL (1) PL3096756T3 (https=)
PT (1) PT3096756T (https=)
RS (1) RS65839B1 (https=)
RU (1) RU2718918C2 (https=)
SI (1) SI3096756T1 (https=)
SM (1) SMT202400361T1 (https=)
WO (1) WO2015112642A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015112642A1 (en) 2014-01-21 2015-07-30 Neurocrine Biosciences, Inc. Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
CA2940242C (en) 2014-02-20 2026-01-13 H. Lundbeck A/S Anti-acth antibodies and use thereof
EP3510029B1 (en) 2016-09-07 2025-11-05 The Regents of The University of California Allosteric corticotropin-releasing factor receptor 1 (crfr1) antagonists that decrease p-tau and improve cognition
CN118845788A (zh) 2017-08-14 2024-10-29 云杉生物科学公司 促肾上腺皮质激素释放因子受体拮抗剂
EP4438124A3 (en) 2018-04-27 2024-12-18 Spruce Biosciences, Inc. Methods for treating testicular and ovarian adrenal rest tumors
JP7532328B2 (ja) * 2018-12-07 2024-08-13 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 先天性副腎過形成を処置するためのｃｒｆ１受容体アンタゴニスト、その医薬製剤および固体形態
CA3121920A1 (en) * 2018-12-07 2020-06-11 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
TW202116324A (zh) * 2019-07-19 2021-05-01 美商雲杉生物科技股份有限公司 治療先天性腎上腺增生之方法
JP7623365B2 (ja) * 2019-09-27 2025-01-28 ニューロクライン バイオサイエンシーズ，インコーポレイテッド Ｃｒｆ受容体アンタゴニストおよび使用方法
IL298901A (en) * 2020-06-10 2023-02-01 Neurocrine Biosciences Inc A CRF1 receptor antagonist for the treatment of congenital adrenal hyperplasia
BR112023002497A2 (pt) * 2020-08-12 2023-05-02 Spruce Biosciences Inc Métodos e composições para tratamento da síndrome dos ovários policísticos
MD20210019A2 (ro) 2021-04-12 2022-10-31 Максим МАСЮТИН Metodă de tratament a hiperplaziei suprarenale congenitale, cauzate de deficit de 21-hidroxilază cu debut tardiv prin regimul de glucocorticoizi adaptat individual
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4949582B1 (https=) 1969-01-20 1974-12-27
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
FR2692893B1 (fr) 1992-06-24 1994-09-02 Sanofi Elf Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
US6664261B2 (en) 1996-02-07 2003-12-16 Neurocrine Biosciences, Inc. Pyrazolopyrimidines as CRF receptor antagonists
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
US6159980A (en) 1996-09-16 2000-12-12 Dupont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
FR2754258B1 (fr) 1996-10-08 1998-12-31 Sanofi Sa Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
ES2207834T3 (es) 1997-04-22 2004-06-01 Janssen Pharmaceutica N.V. Quino- y quinazolinas antagonistas del crf.
AU9021598A (en) 1997-08-22 1999-03-16 Du Pont Pharmaceuticals Company Nitrogen substituted imidazo{4,5-c}pyrazoles as corticotropin relea sing hormone antagonists
US6531475B1 (en) 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
WO2000059888A1 (en) 1999-04-02 2000-10-12 Neurogen Corporation N-benzimidazolylmethyl- and n-indolylmethyl-benzamides and their use as crf modulators
FR2796380B3 (fr) 1999-07-15 2001-08-17 Sanofi Synthelabo Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant
FR2802530B1 (fr) 1999-12-17 2002-02-22 Sanofi Synthelabo Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant
WO2003006015A1 (en) 2001-07-13 2003-01-23 Bristol-Myers Squibb Pharma Company Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands
WO2005079807A1 (en) 2004-02-13 2005-09-01 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
WO2006124047A2 (en) 2004-08-13 2006-11-23 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
DE602005014375D1 (de) 2004-10-19 2009-06-18 Neurocrine Biosciences Inc Crf-rezeptor-antagonisten und zugehörige verfahren
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
AU2006227300B2 (en) 2005-03-21 2012-02-02 Eli Lilly And Company Imidazopyridazine compounds
WO2006107784A1 (en) 2005-04-05 2006-10-12 Eli Lilly And Company Imidazopyridazine compounds
TWI370820B (en) 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
EP1903045A1 (en) 2005-05-27 2008-03-26 Mitsubishi Tanabe Pharma Corporation Pyrazolopyrimidine derivative
JP5377968B2 (ja) 2005-11-10 2013-12-25 トポターゲット ユーケー リミテッド 癌治療のために単独で用いるまたは化学療法薬と併用するヒストンデアセチラーゼ（ｈｄａｃ）阻害剤
EP1961745A1 (en) 2005-12-12 2008-08-27 Ono Pharmaceutical Co., Ltd. Bicyclic heterocyclic compound
EP1961754A4 (en) 2005-12-15 2009-11-11 Ono Pharmaceutical Co BICYCLIC HETEROCYCLIC COMPOUND
ES2435793T3 (es) 2006-02-07 2013-12-23 Phenoquest Ag Procedimientos para el tratamiento de trastornos afectivos
EP1834641A1 (en) 2006-03-16 2007-09-19 Sanofi-Aventis Use of CRF1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia
US20090306137A1 (en) 2006-05-22 2009-12-10 Wolfgang Curt D Treatment for depressive disorders
EP2094709B1 (en) * 2006-09-20 2010-09-15 Eli Lilly And Company Thiazole pyrazolopyrimidines as crf1 receptor antagonists
AU2007297481B2 (en) 2006-09-20 2012-03-08 Eli Lilly And Company Thiophene pyrazolopyrimidine compounds
US20100056515A1 (en) 2006-10-25 2010-03-04 Kazuyoshi Aso Benzimidazole compounds
JP2010514672A (ja) 2006-12-29 2010-05-06 武田薬品工業株式会社 Ｃｒｆアンタゴニスト活性を有する縮合複素環化合物
WO2008083070A1 (en) 2006-12-29 2008-07-10 Neurogen Corporation Crf1 receptor ligands comprising fused bicyclic heteroaryl moieties
TW200902019A (en) 2007-04-26 2009-01-16 Ono Pharmaceutical Co Dicyclic heterocyclic compound
WO2009008552A1 (en) 2007-07-11 2009-01-15 Taisho Pharmaceutical Co., Ltd. 8-aryl-4-alkylpyrrolo[2,3,4-de]quinolin-5(4h)-one and 8-aryl-4-alkyl-4,5-dihydropyrrolo[2,3,4-de]quinolin-5-ol derivatives
WO2009144632A1 (en) 2008-05-30 2009-12-03 Pfizer Limited Novel compounds
US7932256B2 (en) 2008-07-31 2011-04-26 Bristol-Myers Squibb Company (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity
CN102105149A (zh) 2008-07-31 2011-06-22 百时美施贵宝公司 作为促肾上腺皮质激素释放因子受体活性调节剂的取代的氨基甲酸酯衍生物
US7994203B2 (en) 2008-08-06 2011-08-09 Novartis Ag Organic compounds
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
CN102245117B (zh) 2008-11-03 2014-04-16 斯恩蒂斯有限公司 可调节的杆组件
US8551996B2 (en) 2009-02-20 2013-10-08 Emory University Compounds, compositions, methods of synthesis, and methods of treatment
HUP0900267A2 (en) 2009-04-30 2011-03-28 Sanofi Aventis Process for preparing of thiazole amines and intermediates thereof
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
JPWO2011043387A1 (ja) 2009-10-08 2013-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロオキサゾール化合物
WO2011092290A1 (en) 2010-02-01 2011-08-04 Novartis Ag Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
SG10201912111TA (en) 2012-04-13 2020-02-27 Epizyme Inc Combination therapy for treating cancer
EP2841595A2 (en) * 2012-04-23 2015-03-04 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Genetic predictors of response to treatment with crhr1 antagonists
HK1207304A1 (en) 2012-04-23 2016-01-29 Hmnc Value Gmbh Crhr1 antagonists for use in the treatment of patients having crh overactivity
WO2015112642A1 (en) 2014-01-21 2015-07-30 Neurocrine Biosciences, Inc. Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
WO2016065177A1 (en) 2014-10-22 2016-04-28 The Trustees Of The University Of Pennsylvania Method of treating depression and other stress related disorders
CA2974540C (en) 2015-02-06 2023-09-26 Neurocrine Biosciences, Inc. [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
WO2016156576A1 (en) 2015-04-02 2016-10-06 Hmnc Value Gmbh Method of treatment using genetic predictors of a response to treatment with crhr1 antagonists
WO2018012066A1 (ja) * 2016-07-14 2018-01-18 株式会社コナミデジタルエンタテインメント ゲームシステム、端末装置及びプログラム
JP7595413B2 (ja) 2016-11-30 2024-12-06 ケース ウエスタン リザーブ ユニバーシティ １５－ｐｇｄｈ阻害剤とコルチコステロイドおよび／またはｔｎｆ阻害剤との組み合わせならびにその使用
WO2018219804A1 (en) 2017-06-02 2018-12-06 Bayer Pharma Aktiengesellschaft Self-microemulsifying drug delivery systems
CN118845788A (zh) 2017-08-14 2024-10-29 云杉生物科学公司 促肾上腺皮质激素释放因子受体拮抗剂
EA202090321A1 (ru) 2017-08-14 2020-09-24 Спрюс Биосайнсес, Инк. Антагонисты рецептора кортикотропин-рилизинг фактора
EP4438124A3 (en) * 2018-04-27 2024-12-18 Spruce Biosciences, Inc. Methods for treating testicular and ovarian adrenal rest tumors
CA3121920A1 (en) 2018-12-07 2020-06-11 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
TW202116324A (zh) 2019-07-19 2021-05-01 美商雲杉生物科技股份有限公司 治療先天性腎上腺增生之方法
JP7623365B2 (ja) 2019-09-27 2025-01-28 ニューロクライン バイオサイエンシーズ，インコーポレイテッド Ｃｒｆ受容体アンタゴニストおよび使用方法
WO2021113263A1 (en) 2019-12-04 2021-06-10 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
IL298901A (en) 2020-06-10 2023-02-01 Neurocrine Biosciences Inc A CRF1 receptor antagonist for the treatment of congenital adrenal hyperplasia
JP2023540223A (ja) 2020-08-26 2023-09-22 ニューロクライン バイオサイエンシーズ，インコーポレイテッド Ｃｒｆ受容体アンタゴニストおよび使用方法

Also Published As

Publication number Publication date
RU2020112197A (ru) 2020-05-21
IL317035A (en) 2025-01-01
IL304134B1 (en) 2024-12-01
BR112016016975B1 (pt) 2022-12-27
DK3096756T3 (da) 2024-08-05
US20210137926A1 (en) 2021-05-13
PT3096756T (pt) 2024-08-26
AU2020207774A1 (en) 2020-08-06
US20190231781A1 (en) 2019-08-01
US11311544B2 (en) 2022-04-26
KR102258522B1 (ko) 2021-05-31
AU2015209452A1 (en) 2016-08-04
JP7104743B2 (ja) 2022-07-21
IL286782A (en) 2021-10-31
AU2022263460B2 (en) 2024-10-17
US11730739B2 (en) 2023-08-22
RS65839B1 (sr) 2024-09-30
US20170020877A1 (en) 2017-01-26
KR20160106176A (ko) 2016-09-09
EP4450070A1 (en) 2024-10-23
AU2022263460A1 (en) 2022-12-08
US20240058342A1 (en) 2024-02-22
AU2020207774B2 (en) 2022-08-04
AU2015209452C1 (en) 2020-11-05
JP2024098001A (ja) 2024-07-19
FI3096756T3 (fi) 2024-08-14
WO2015112642A1 (en) 2015-07-30
IL246783B (en) 2021-10-31
IL296683B1 (en) 2023-08-01
IL296683B2 (en) 2023-12-01
EP3096756B1 (en) 2024-06-12
BR112016016975A2 (pt) 2017-08-08
ES2984706T3 (es) 2024-10-30
RU2016133972A3 (https=) 2018-09-26
US20210361659A1 (en) 2021-11-25
MX2022000080A (es) 2022-02-03
JP2019081814A (ja) 2019-05-30
AU2024219813A1 (en) 2024-10-10
RU2016133972A (ru) 2018-03-05
CA2936974A1 (en) 2015-07-30
SMT202400361T1 (it) 2024-11-15
CN106102740A (zh) 2016-11-09
JP2020138978A (ja) 2020-09-03
SI3096756T1 (sl) 2024-09-30
KR20210064407A (ko) 2021-06-02
MX389004B (es) 2025-03-20
AU2015209452B2 (en) 2020-05-07
CA3155599A1 (en) 2015-07-30
HUE068315T2 (hu) 2024-12-28
US10905690B2 (en) 2021-02-02
JP6936825B2 (ja) 2021-09-22
IL304134B2 (en) 2025-04-01
EP3096756A1 (en) 2016-11-30
MX2016009499A (es) 2017-02-27
JP6585625B2 (ja) 2019-10-02
NZ722122A (en) 2020-06-26
IL246783A0 (en) 2016-08-31
IL304134A (en) 2023-09-01
MX2021012539A (es) 2021-11-12
RU2718918C2 (ru) 2020-04-15
CN111228274A (zh) 2020-06-05
PL3096756T3 (pl) 2024-10-28
LT3096756T (lt) 2024-08-26
IL296683A (en) 2022-11-01
JP2022010260A (ja) 2022-01-14
JP2017503030A (ja) 2017-01-26

Similar Documents

Publication Publication Date Title
HRP20241046T1 (hr) Antagonisti crf1 receptora za liječenje kongenitalne adrenalne hiperplazije
CY1120934T1 (el) Νευροδραστικα στεροειδη και μεθοδοι χρησης αυτων
Deinum et al. Pharmacological treatment of aldosterone excess
WO2018013918A3 (en) Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
PH12018500586B1 (en) Farnesoid x receptor agonists and uses thereof
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
IL261548B (en) 7α,β11-dihydroxy-6α-ethyl-5β-cholan-24-oic acid and its use for the treatment of paranoid x receptor activated conditions
NZ737399A (en) Ccr2 modulators
NI201600029A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para el tratamiento de la tos aguda, sub-aguda o crónica.
PH12015502621A1 (en) Estrogen receptor modulator and uses thereof
Adler et al. Glucocorticoid-induced osteoporosis
MX2016011902A (es) Medicamentos de administracion nasal y metodos para su uso.
SG11202102349PA (en) Compositions and methods for treating disorders ameliorated by muscarnic receptor activation
PH12016502556A1 (en) Intermittent dosing of mdm2 inhibitor
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
MX2017003638A (es) Microparticulas inyectables para liberacion hiper-localizada de agentes terapeuticos.
PH12017500239A1 (en) Abiraterone acetate formulation and methods of use
WO2018222781A3 (en) Compositions and methods to regulate hormonal cascades in stress disorders
PH12021550671A1 (en) Prodrugs of cgrp antagonists
MX2024013184A (es) Metodos y composiciones para tratar apnea del sue?o
MX2020010086A (es) Métodos y composiciones para tratar alucinaciones y afecciones relacionadas con las mismas.
UY33529A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?
HRP20201315T1 (hr) Pripravak koji sadrži hidrokortizon
AU2017257603A1 (en) Highly selective adenosine A3 receptor subtype agonsists for the prevention and treatment of neurodegenerative disorders
TN2017000482A1 (en) Selective progesterone receptor modulator (sprm) regimen.